In conclusion, our results demonstrated that isorhamnetin could be a very useful hypoglycemic agent for the treatment of T2D due to its multifactorial effects including (i) the reduction in insulin resistance, (ii) an increase in glucose uptake by the skeletal muscle, (iii) improvement in the lipid profile, (iv) reduction in oxidative stress and inflammation and (v) the activation of the GLUT4-AMPK pathway. The gene discussed is SLC2A4; the disease is Insulin resistance.